NLU PG aspirant challenges ‘exorbitant' counselling fee, HC sends notice
New Delhi:
Delhi High Court
declined any interim relief to a Common Law Admission Test (CLAT) postgraduate candidate who complained that the counselling fee charged by the consortium of National Law Universities (NLUs) was "exorbitant".
Justice Rajneesh Kumar Gupta, however, sought the stand of the consortium, Bar Council of India, University Grants Commission, central govt and others by July 2.
In his plea, the candidate said he could not participate in the second round of counselling on June 20 as the rules mandated he deposit Rs 20,000 as "upfront payment" after he already paid Rs 30,000 as a refundable counselling fee for the first round. The plea assailed Clause 2, Admissions Counselling Process, which provides for a freeze option, where whenever any candidate wants to book a spot, he is required to deposit a "non-refundable confirmation fee" of Rs 20,000.
You Can Also Check:
Delhi AQI
|
Weather in Delhi
|
Bank Holidays in Delhi
|
Public Holidays in Delhi
Questioning why this fee is payable at every round whenever the candidate opts to freeze any seat, the plea says a candidate thus may be charged even multiple times, considering there are three rounds of counselling. "Thus, via various sub-clauses of Clause 2.1, for the 2nd and 3rd/final round of counselling, the candidate would be required to pay a non-refundable amount of Rs 20,000-40,000 only for freezing their seat in both the rounds," the petition argued, saying such a steep fee has "absolutely no nexus" with the counselling's stated purpose and creates a financial barrier for many students.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Falta Apenas 1 Minuto para Garantir Seu Aparelho Grátis
Aparelhos Auditivo PT
Undo
"I cannot participate without making payment of Rs 20,000 for per-round participation… This is the only exam in the whole country which charges such a large amount. Hundreds of students are not able to participate in the counselling. I missed the second round and the third round is on July 4," the counsel argued.
The court refused the plea for interim relief in the form of a waiver, but posted it for further hearing next month.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
18 minutes ago
- Economic Times
Influx Healthtech shares list at 38% premium over IPO price on NSE SME
Influx Healthtech debuted strongly on the NSE SME platform, listing at Rs 132.5 per share, a 38% premium over its IPO price of Rs 96. The Rs 58.57 crore IPO, which closed on June 20, surpassed grey market expectations. Tired of too many ads? Remove Ads IPO Overview Tired of too many ads? Remove Ads Popular in Markets 1. HAL shares in focus as delay-hit Tejas jets to reach IAF by March Company background Financials and Valuation Healthcare-focused contract manufacturer Influx Healthtech made a strong debut on the NSE SME platform today, listing at Rs 132.5 per share, a 38% premium over its IPO price of Rs Rs 58.57 crore IPO had closed for subscription on June of the listing, the grey market premium (GMP) for Influx Healthtech stood at around Rs 20, implying an expected listing price of Rs 116 — a potential gain of 20.83%. However, the stock surpassed grey market expectations with a significantly stronger IPO comprised a fresh issue of 50 lakh shares worth Rs 48 crore and an offer for sale (OFS) of 11 lakh shares worth Rs 10.56 crore, offering a total of 61,00,800 shares. The IPO price was fixed at Rs 96 per anchor portion attracted Rs 16.67 crore, with shares allocated to institutional investors a day before the issue in 2020, Influx Healthtech is a CDMO (Contract Development and Manufacturing Organization) providing end-to-end manufacturing and product development services for nutraceuticals, cosmetics, personal care, ayurvedic, veterinary, and homecare out of three modern facilities in Thane, Maharashtra, the company boasts an extensive portfolio including gummies, capsules, powders, skincare products, herbal supplements, and veterinary feed formulations. It serves nutraceutical, cosmetic, and healthcare clients, handling everything from formulation and R&D to regulatory support and company currently employs 163 people and continues to expand its product capabilities and client reach, focusing on innovation and scalability in fast-growing consumer health Healthtech posted a revenue of Rs 104.99 crore in FY25, up 5% year-on-year, while PAT rose 19% to Rs 13.37 crore. It maintains a robust ROE of 36.98%, EBITDA margin of 19.62%, and negligible debt.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Time of India
30 minutes ago
- Time of India
MCX shares jump 5% to hit all-time high as UBS hikes target price to Rs 10,000
MCX shares rose sharply after global brokerage firm UBS raised its target price to Rs 10,000 from Rs 7,000, citing strong volume growth and new product launches like electricity derivatives and silver options. The brokerage expects continued momentum in trading revenue and profitability amid rising commodity volatility and product diversification. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Popular in Markets 1. HAL shares in focus as delay-hit Tejas jets to reach IAF by March MCX share price performance Global brokerage firm UBS has raised its target price on MCX shares to Rs 10,000, up from an earlier target price of Rs 7,000, while maintaining a 'Buy' rating on the same. Following the update, the shares of MCX rallied 5% to their all-time high of Rs 8,620 on the brokerage expects increased volatility in key commodities to support volume expansion on the exchange. UBS also highlighted an improving pace and visibility of new product launches, which could further boost investor has seen strong trading volumes since April, with futures' average daily value (ADV) rising around 50% QoQ and options premiums ADV up 30% QoQ. Analysts at UBS expect this strength to persist amid geopolitical launches—like electricity derivatives, monthly bullion contracts, and upcoming index options—are likely to support near-to-medium-term recently launched electricity derivatives and monthly silver options. Initial analysis by the global brokerage firm suggests electricity derivatives could contribute 3–12% to revenue, with a conservative estimate of 3% in FY28 and room for options are expected to gain traction due to a preference for near-expiry context, after launching monthly gold options in November 2024, premium ADVs rose from Rs 1–2 bn to Rs 4–6 bn, and monthly contracts made up 80–95% of gold premium ADVs. These new launches are expected to support near-to-medium-term reported a sharp jump in Q1 trading volumes, with futures ADV rising ~50% QoQ from the earlier stable range of Rs 270–280 billion, driven primarily by increased activity in gold and premiums' ADV also grew 30% QoQ, reaching Rs 43 billion. Based on these trends, analysts estimate trading revenue growth of 34–35% QoQ and a 50% increase in PAT, aided by the absorption of seasonal Q4 expenses like higher staffing and license on these trends, UBS has raised its FY27–FY28 earnings per share (EPS) estimates by 13–17%. MCX is currently trading at around 42x FY27E PE, and analysts believe the market is not yet fully factoring in the exchange's new product growth potential and volume-led margin the past year, MCX shares have delivered an impressive 117.28% return. The stock is up 36.27% year-to-date (YTD), while gaining 35% over the last six months. In the past three months alone, the stock has surged 66.11%, and in the most recent one-month period, it has risen 31.96%.Around 10:45 am, the shares of MCX were trading 4.6% higher at Rs 8,591.35 on the BSE.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
30 minutes ago
- Time of India
Ellenbarrie Industrial Gases IPO GMP rises to 6%; issue subscribed 9% on Day 2
The initial public offering (IPO) of Ellenbarrie Industrial Gases was subscribed 9% so far on the second day of bidding on Wednesday, up from 8% on Day 1. As of 10:03 am, the IPO had received bids for 12,95,222 shares, or 9% of the total issue size of 1,51,08,983 shares. The retail investor portion was subscribed 15%, while the non-institutional investor (NII) category saw a 9% subscription. The qualified institutional buyer (QIB) segment was yet to be subscribed. In the grey market, Ellenbarrie Industrial Gases shares were trading at a premium of Rs 25–26, up from Rs 7–9 on Day 1. This means the GMP has risen to around 6% from 1.75%. Also Read: These 10 penny stocks under Rs 10 surged 200-570% in last 1 year. Do you own any? IPO details Live Events The public issue includes a fresh equity issuance worth Rs 400 crore along with an offer for sale (OFS) of 1.13 crore shares. Ahead of the launch, the company successfully secured Rs 256 crore from anchor investors. The price band has been set at Rs 380 to Rs 400 per share, with a minimum application size of 37 shares. The shares are proposed to be listed on both the NSE and BSE. The IPO proceeds will be utilised to repay debt amounting to Rs 210 crore, establish a 220 TPD air separation unit at the company's Uluberia-II plant at a cost of Rs 104.5 crore, and meet general corporate requirements. Eastern India Gases Ltd (EIGL) also plans to commission three new plants by FY26, aiming to increase its total installed capacity from 3,861 TPD to 4,551 TPD. Also Read: Jio Financial surges over 50% from March lows: Will the momentum sustain? About Ellenbarrie Industrial Gases Founded over five decades ago, EIGL manufactures and supplies a wide range of industrial gases such as oxygen, nitrogen, argon, and acetylene, along with speciality gases, medical gases, and cryogenic storage systems. It operates nine facilities across East, South, and Central India, servicing industries like steel, pharmaceuticals, defence, healthcare, and railways. The company reported a 26.7% PAT margin in FY25 with net profit of Rs 83.3 crore, EBITDA margin of 35.8%, and return on equity of 16.9%. At the upper end of the price band, the stock is valued at 62.9x FY25 earnings. Also Read: Coforge among 10 high-conviction stock ideas that can rally up to 52% Should you subscribe to the Ellenbarrie Industrial Gases IPO? SBI Securities has rated the IPO as Subscribe, citing EIGL's improving margin profile, strong client base, strategic capacity expansion, and attractive valuation compared to listed peers like Linde India . ( Disclaimer : Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of Economic Times)
